PRDM9 and cancer: With epigenetic reprogramming by pharmacological intervention receiving critical recognition and showing considerable promise in cancer trials33,34, we decided to explore the function of DZNep on HRECs and elucidate the effects of inhibiting histone methyltransferases on MALAT1 and inflammation in a diabetic environment.